Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreserVcyt medium

Journal of Clinical Microbiology

Volumn 50, Issue 1, 2012, Pages 25-29

  Wong, Anita A ^a   Fuller, Jeff ^a,b   Pabbaraju, Kanti ^a   Wong, Sallene ^a   Zahariadis, George ^a,b  

^a PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; CANADA; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION;

ADOLESCENT; ADULT; ALBERTA; CULTURE MEDIA; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES AS TOPIC; SPECIMEN HANDLING; VIROLOGY; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

EID: 84555178949     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05400-11     Document Type: Article

References (33)

1. Bachtiary B, et al. 2002. Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. Int. J. Cancer 102:237-243. (Pubitemid 35222290)
2. Bernard H-U, Burk RD, Chen Z, van Doorslaer DK, zur Hausen de Villiers E-M. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79.
3. Bosch FX, de Sanjosé S. 2003. Chapter 1: human papillomavirus and cervical cancer - burden and assessment of causality. J. Natl. Cancer Inst. Monogr. 31:3-13.
4. Castle PE, et al. 2009. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J. Clin. Microbiol. 47:3344-3347.
5. Castle PE, et al. 2002. Restricted cross-reactivity of Hybrid Capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev. 11:1394-1399. (Pubitemid 35340375)
6. Castle PE, et al. 2008. Human papillomavirus genotype specificity of Hybrid Capture 2. J. Clin. Microbiol. 46:2595-2604.
7. Cuschieri KS, et al. 2005. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J. Clin. Pathol. 58:946-950. (Pubitemid 41265279)
8. Cuschieri KS, et al. 2004. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J. Clin. Pathol. 57:68-72. (Pubitemid 38091314)
9. Cuzick J, et al. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101. (Pubitemid 44116919)
10. Dalstein V, et al. 2003. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int. J. Cancer 106:396-403. (Pubitemid 36870403)
11. de Antonio JC, Fernández-Olmos A, Mercadillo M, Lindemann MLM, Mochales FB. 2008. Detection of high-risk human papillomavirus by two molecular techniques: Hybrid Capture and Linear Array. J. Virol. Methods 149:163-166.
12. Fife KH, Cramer HM, Schroeder JM, Brown DR. 2001. Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. J. Med. Virol. 64:550-559. (Pubitemid 32613745)
13. Franco EL, Duarte-Franco E, Ferenczy A. 2001. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 164:1017-1025. (Pubitemid 34412231)
14. Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE. 2008. A comparison of Linear Array and Hybrid Capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol. Biomarkers Prev. 17:1248-1254.
15. Heideman DAM, et al. 2011. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J. Clin. Microbiol. 49:3983-3985.
16. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338:423-428. (Pubitemid 28135669)
17. IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. 1986. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Br. Med. J. 293:659-664.
18. Lee SA, et al. 2003. Multiple HPV infection in cervical cancer screened by HPVDNAChip. Cancer Lett. 198:187-192. (Pubitemid 37303950)
19. Lörincz AT, Richart RM. 2003. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch. Pathol. Lab Med. 127:959-968. (Pubitemid 36994855)
20. Monsonego J, et al. 2008. Detection of human papillomavirus genotypes among high-risk women: a comparison of Hybrid Capture and Linear Array tests. Sex. Transm. Dis. 35:521-527. (Pubitemid 351670554)
21. Muñoz N, et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527. (Pubitemid 36159887)
22. Petry K-U, et al. 2003. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br. J. Cancer 88:1570-1577. (Pubitemid 36713784)
23. Poljak M, Marin IJ, Seme K, Vince A. 2002. Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol. 25(Suppl. 3):S89-S97. (Pubitemid 35441020)
24. Ratnam S, Franco EL, Ferenczy A. 2000. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomarkers Prev. 9:945-951.
25. Rolón PA, et al. 2000. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int. J. Cancer 85:486-491. (Pubitemid 30075125)
26. Schiffman M, Clifford G, Buonaguro FM. 2009. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agents Cancer. 4:8.
27. Schlecht NF, et al. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286:3106-3114. (Pubitemid 34016525)
28. Stevens MP, et al. 2007. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J. Clin. Microbiol. 45:2130-2137. (Pubitemid 47203782)
29. Stoler MH, et al. 2011. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am. J. Clin. Pathol. 135:468-475.
30. Wallin K-L, et al. 1999. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Engl. J. Med. 341:1633-1638.
31. Wheeler CM, Hunt WC, Schiffman M, Castle PE. 2006. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J. Infect. Dis. 194:1291-1299. (Pubitemid 44630975)
32. Wright TC, Jr, et al. 2007. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low. Genit. Tract Dis. 11:201-222.
33. zur Hausen H. 2009. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384:260-265.